Marthas M L, van Rompay K K, Otsyula M, Miller C J, Canfield D R, Pedersen N C, McChesney M B
California Regional Primate Research Center, University of California, Davis 95616, USA.
J Virol. 1995 Jul;69(7):4198-205. doi: 10.1128/JVI.69.7.4198-4205.1995.
To evaluate how viral variants may affect disease progression in human pediatric AIDS, we studied the potential of three simian immunodeficiency virus (SIV) isolates to induce simian AIDS in newborn rhesus macaques. The three virus isolates were previously shown to range from pathogenic (SIVmac251 and SIVmac239) to nonpathogenic (SIVmac1A11) when inoculated intravenously into juvenile and adult rhesus macaques. Six newborn macaques inoculated with pathogenic, uncloned SIVmac251 developed persistent, high levels of cell-associated and cell-free viremia, had no detectable antiviral antibodies, and had poor weight gain; these animals all exhibited severe clinical disease and pathologic lesions diagnostic for simian AIDS and were euthanatized 10 to 26 weeks after inoculation. Two newborns inoculated with pathogenic, molecularly cloned SIVmac239 developed persistent high virus load in peripheral blood, but both animals had normal weight gain and developed antiviral antibodies. One of the SIVmac239-infected neonates exhibited pathologic lesions diagnostic for SAIDS and was euthanatized at 34 weeks after inoculation; the other SIVmac239-infected neonate remained alive and exhibited no significant clinical disease for more than 1 year after inoculation. In contrast, three newborn rhesus macaques inoculated with the nonpathogenic molecular clone, SIVmac1A11, had transient, low-level viremia, seroconverted by 10 weeks after inoculation, had normal weight gain, and remained healthy for over 1 year. These results indicate that (i) newborn rhesus macaques infected with an uncloned, virulent SIVmac isolate have a more rapid, fulminant disease course than do adults inoculated with the same virus, (ii) the most rapid disease progression is associated with lack of a detectable humoral immune response in SIV-infected infant macaques, (iii) a molecularly cloned, attenuated SIV isolate is nonpathogenic in neonatal macaques, and (iv) SIV-infected neonatal macaques exhibit patterns of infection, virus load, and disease progression similar to those observed in human immunodeficiency virus-infected children. This SIV/neonatal rhesus model of pediatric AIDS provides a rapid, sensitive model with which to compare the virulence of SIV isolates and to study the mechanisms underlying the differences in disease progression in human immunodeficiency virus-infected infants.
为了评估病毒变异体如何影响人类儿童艾滋病的疾病进展,我们研究了三种猿猴免疫缺陷病毒(SIV)分离株在新生恒河猴中诱发猿猴艾滋病的潜力。先前的研究表明,将这三种病毒分离株静脉注射到幼年和成年恒河猴体内时,其致病性范围从致病性(SIVmac251和SIVmac239)到非致病性(SIVmac1A11)。六只接种了致病性、未克隆的SIVmac251的新生猕猴出现了持续的、高水平的细胞相关和无细胞病毒血症,未检测到抗病毒抗体,体重增加不佳;这些动物均表现出严重的临床疾病和诊断为猿猴艾滋病的病理病变,并在接种后10至26周实施安乐死。两只接种了致病性、分子克隆的SIVmac239的新生猕猴外周血中出现持续的高病毒载量,但两只动物体重均正常增加,并产生了抗病毒抗体。其中一只感染SIVmac239的新生儿表现出诊断为SAIDS的病理病变,并在接种后34周实施安乐死;另一只感染SIVmac239的新生儿存活下来,接种后1年多未出现明显的临床疾病。相比之下,三只接种了非致病性分子克隆SIVmac1A11的新生恒河猴出现短暂的低水平病毒血症,接种后10周血清转化,体重正常增加,并在1年多的时间里保持健康。这些结果表明:(i)感染未克隆的、毒性强的SIVmac分离株的新生恒河猴比接种相同病毒的成年恒河猴疾病进程更快、更暴发性;(ii)最快的疾病进展与SIV感染的幼年猕猴中缺乏可检测到的体液免疫反应有关;(iii)分子克隆的、减毒的SIV分离株在新生猕猴中无致病性;(iv)SIV感染的新生猕猴表现出的感染模式、病毒载量和疾病进展与人类免疫缺陷病毒感染儿童中观察到的相似。这种小儿艾滋病的SIV/新生恒河猴模型提供了一个快速、敏感的模型,可用于比较SIV分离株的毒力,并研究人类免疫缺陷病毒感染婴儿疾病进展差异的潜在机制。